Skip to main content

Market Overview

MannKind's Short Interest Has 'Grown High,' Analyst Says

Share:

In a report published Monday, Goldman Sachs analyst Jay Olson pointed out that the short interest in shares of MannKind Corporation (NASDAQ: MNKD) has "grown high" over the past two years.

According to Olson, the rise in short interest can be attributed to key catalysts including FDA approval and signing of a commercial collaboration agreement. The analyst added that the days to cover has been variable but generally fluctuating around 10 days.

Olson also noted that the issuance of $100 million in convertible debt with a conversion ratio of approximately 147 shares per $1,000 face value of debt accounted for approximately 14.7 million shares, or about 17 percent of outstanding short interest in MannKind. Finally, short interest net of the convertible debt is currently about 28 percent.

Shares were downgraded to Sell from Neutral with a price target lowered to $3 from a previous $6.

Shares of MannKind recently traded at $6, down 9.6 percent.

Latest Ratings for MNKD

DateFirmActionFromTo
Dec 2019OppenheimerInitiates Coverage OnOutperform
May 2019BTIG ResearchInitiates Coverage OnBuy
Mar 2019Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

 

Related Articles (MNKD)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs Jay Olson short interestAnalyst Color Downgrades Price Target FDA Analyst Ratings

Latest Ratings

StockFirmActionPT
FSRMorgan StanleyMaintains40.0
NATJefferiesMaintains2.8
MEDDA DavidsonMaintains302.0
VICRBWS FinancialMaintains120.0
PSXMizuhoMaintains96.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com